Novartis Says Kisqali Significantly Lowered the Risk of Cancer Recurrence
June 02 2023 - 8:49AM
Dow Jones News
By Giulia Petroni
Novartis said that primary endpoint data from a Phase 3 trial
showed that ribociclib drug treatment Kisqali significantly reduced
the risk of cancer recurrence across a broad population of patients
with early breast cancer.
The Swiss pharma giant on Friday said that ribociclib combined
with endocrine therapy lowered the risk of cancer recurrence by
25.2% in patients compared to endocrine therapy alone, according to
data from the Natalee trial.
The patients suffer from stage 2 and 3 hormone
receptor-positive/human epidermal growth factor receptor 2-negative
early breast cancer, according to the company.
"Kisqali is the first and only CDK4/6 inhibitor to demonstrate a
consistent, clinically meaningful benefit across a broad population
of patients with early breast cancer, regardless of disease stage,
menopausal or nodal status," Novartis said.
Novartis plans to submit Phase 3 data to regulatory authorities
in the U.S. and Europe before end of year.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
June 02, 2023 08:33 ET (12:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
